Table 2

Vaccine efficacy against VMCCI, CCI, and LCI in the Per-Protocol analyses.

Season 1

2005-2006

Season 2

2006-2007

Overall

Overall efficacy (97.5% CI lower bound)


Vaccine

N = 1706

n (%)

Placebo

N = 1725

n (%)

Vaccine

N = 2011

n (%)

Placebo

N = 2043

n (%)

Vaccine

N = 3714

n (%)

Placebo

N = 3768

n (%)


VMCCI

14 (0.8)

30 (1.7)

9 (0.4)

15 (0.7)

23 (0.6)

45 (1.2)

46.3% (9.8%)

CCI

19 (1.1)

38 (2.2)

11 (0.5)

22 (1.1)

30 (0.8)

60 (1.6)

49.4% (20.3%)

LCI

24 (1.4)

69 (4.0)

20 (1.0)

53 (2.6)

44 (1.2)

122 (3.2)

63.2% (48.2%)


VMCCI, culture-confirmed influenza A and B matching vaccine; CCI, any culture-confirmed influenza A and B; LCI, any culture- or serology-confirmed influenza A or B; CI, Confidence Interval

Jackson et al. BMC Infectious Diseases 2010 10:71   doi:10.1186/1471-2334-10-71

Open Data